TLX
Director Trades
| Date | Director | Value |
|---|---|---|
| M. McDonald | $100,078 | |
| T. Olson | $319,422 | |
| H. McCann | $912,900 | |
| C. Behrenbruch | $59,000,000 |
Company News
Telix Pharmaceuticals to acquire Canadian isotope innovator ARTMS in $125.9m deal
Australian biopharmaceutical company Telix Pharmaceuticals (ASX: TLX) is set to acquire Canadian radioisotope technology firm ARTMS Inc in a $125.9 million deal designed to boost its supply chain and production capacity. The deal will include ARTMS’ advanced cyclotron-based isotope production platform, a manufacturing plant and a stockpile of ultra-pure rare metals required for consumable target […]
Medibank suffers cyberattack, Telix Pharma expands GE Healthcare partnership and APA Group to acquire Basslink
Health insurance provider Medibank Private’s (ASX: MPL) shares are down this week after the company revealed it suffered a major cyber security incident. Despite the concern, the provider urged there was no evidence of customers’ data being accessed and has since returned to business as usual. Medibank has a large database, covering more than 3.7 […]
Telix withdraws Europe marketing application, AGL to close power station early and BHP prioritises Peru exploration
Telix Pharmaceuticals (ASX: TLX) has announced it has withdrawn its application to market the company’s lead prostate cancer imaging product, Illuccix, in Europe. The Danish Medicines Agency asked for additional chemistry, manufacturing and control data from Telix, but the Australian company said the requests could not be delivered within the prescribed review timeframe. Telix group […]
A2 Milk hopes to join Bubs in alleviating US infant formula crisis, ASIC sues ANZ and Telix Pharma granted pass through
A2 Milk (ASX: A2M) is rallying in its efforts to join rival Bubs Australia (ASX: BUB), which revealed it will export 27.5 million bottles of infant formula products to the United States to help with a nationwide shortage created by the global pandemic. Dual-listed A2 Milk submitted an application to the US Food and Drug […]
Diagnostic imaging: which stock will become the next Pro Medicus?
For all the leaps and bounds in medical science, the know-how behind detecting diseases hasn’t changed much in decades – or even centuries. Take X-rays, which are widely used despite the wee problem of irradiating the patients. And that’s because they are cheap and convenient. The underlying tech hasn’t really moved on since 1895, when […]
FDA grants Telix breakthrough therapy designation for renal cancer imaging product
Clinical-stage biopharmaceutical company Telix Pharmaceuticals (ASX: TLX) has received confirmation from the FDA that its kidney cancer imaging product TLX250-CDx had been granted breakthrough therapy (BT) designation. The company claims to “deliver on the promise of nuclear medicine”, a field of medicine that has historically lacked clinical momentum commitment to late-stage product development. More specifically, […]
Telix Pharmaceuticals to begin phase two prostate cancer imaging study
Biopharmaceutical company Telix Pharmaceuticals (ASX: TLX) has been given the green light to commence a phase two study involving its medical imaging technology on prostate cancer patients. The company today announced it has received regulatory and ethics approvals to begin the study with its strategic partner and leading oncology service provider, GenesisCare. Referred to as […]
Telix Pharmaceuticals partners with Mexican nuclear science firm to advance prostate imaging technology
Australian biopharmaceutical company Telix Pharmaceuticals (ASX: TLX) has completed an in-licensing agremeent with Mexico’s Instituto Nacional de Investigaciones Nucleares (ININ) for a clinical-stage radiopharmaceutical product used in the imaging of prostate cancer. The product – known as 99m-technetium-EDDA/HYNIC-Lys(NaI)-Urea-Glu, or 99m-Tc-iPSMA – will be used as a prostate imaging solution for use with Telix’s single photon […]
Telix Pharmaceuticals acquires Belgium-based Advanced Nuclear Medicine Ingredients
Telix Pharmaceuticals (ASX: TLX) has made a play for Belgium company Advanced Nuclear Medicine Ingredients, with the takeover valuing ANMI at over £5.15 million ($8.07 million). Under the acquisition terms, Telix will issue €3.15 million ($5 million) shares at $0.83 each. In addition to the Telix shares, the company will also pay €2 million cash […]
Telix Pharmaceuticals readies recruitment for phase 3 trial in renal cancer
Melbourne-based biopharmaceutical company Telix Pharmaceuticals (ASX: TLX) is preparing to commence recruitment for its zirconium imaging in renal cancer oncology (ZIRCON) phase 3 trial for imaging of clear cell renal cell cancer (ccRCC) with 89Zr-girentuximab (TLX250), one of the company’s leading therapeutic drugs. TLX250 is being developed as both a therapeutic drug and a diagnostic […]
Company Videos
No videos found.